• B&K reported full patient enrollment in its Phase II trial of Pro-101-2 for diabetic foot ulcers.
• No results were presented; data will be used to assess efficacy and safety ahead of Phase III planning.
• Trial design: randomized, double-blind, placebo-controlled study of recombinant human PDGF-BB gel.
• Enrollment completion marks a key R&D milestone for one of the group’s core products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. B&K Corporation Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260713-12242937), on July 13, 2026, and is solely responsible for the information contained therein.